Premium
Measuring Autoantibodies against IL‐17F and IL‐22 in Autoimmune Polyendocrine Syndrome Type I by Radioligand Binding Assay Using Fusion Proteins
Author(s) -
Oftedal B. E. V.,
Kämpe O.,
Meager A.,
Ahlgren K. M.,
Lobell A.,
Husebye E. S.,
Wolff A. S. B.
Publication year - 2011
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2011.02573.x
Subject(s) - autoantibody , antibody , fusion protein , microbiology and biotechnology , chemistry , immunology , biology , medicine , recombinant dna , biochemistry , gene
Autoantibodies against interleukin (IL)‐17A, IL‐17F and IL‐22 have recently been described in patients with autoimmune polyendocrine syndrome type I (APS I), and their presence is reported to be highly correlated with chronic mucocutaneous candidiasis (CMC). The aim of this study was to develop a robust high‐throughput radioligand binding assays (RLBA) measuring IL‐17F and IL‐22 antibodies, to compare them with current enzyme‐linked immunosorbent assays (ELISA) of IL‐17F and IL‐22 and, moreover, to correlate the presence of these antibodies with the presence of CMC. Interleukins are small molecules, which makes them difficult to express in vitro . To overcome this problem, they were fused as dimers, which proved to increase the efficiency of expression. A total of five RLBAs were developed based on IL‐17F and IL‐22 monomers and homo‐ or heterodimers. Analysing the presence of these autoantibodies in 25 Norwegian APS I patients revealed that the different RLBAs detected anti‐IL‐17F and anti‐IL‐22 with high specificity, using both homo‐ and heterodimers. The RLBAs based on dimer proteins are highly reproducible with low inter‐ and intravariation and have the advantages of high throughput and easy standardization compared to ELISA, thus proving excellent choices for the screening of IL‐17F and IL‐22 autoantibodies.